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DEVELOPMENT AND EVALUATION OF NANOEMULSION FORMULATIONS FOR IMPROVED 
ORAL DELIVERY OF CARVEDILOL 
ABSTRACT 
The aim of the presentinvestigation was to develop, optimize and evaluate nanoemulsion system of carvedilol to 
improve its solubility, and oral bioavailability. Carvedilol is a non-selective beta blocker used in the treatment of 
mild to moderate congestive heart failure and mild to moderate essential hypertension. It has both poor water 
solubility (0.583 mg/L) and oral bioavailability (23%) because of significant first-pass hepatic metabolism. Based on 
solubility testing, clove oil was used as oil, tween 20 was used as surfactants and PEG 400 was used as cosurfactants 
in construction of phase diagrams. Carvedilol nanoemulsions were prepared by aqueous phase titration method. Out 
of twelve formulations, eight thermodynamically stable formulations were selected for preparation of carvedilol 
loaded nanoemulsions and these nanoemulsions were subjected forcharacterization i.e. particle size, viscosity, 
polydispersity, zeta potential. A 12 hrs in-vitro release release study was performed on selected nanoemulsion 
formulations of carvedilol. Study concludes, nanoemulsion formulation of batch NEC4 (Smix  Ratio 1:3) was found to be 
optimum formulation. 
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INTRODUCTION 
The term ‘Nanoemulsions’ is used to designate emulsions with the internal phase droplets havingsizeranging from 
50 to 1000 nm
1
. Nanoemulsions are dispersed particles used for pharmaceutical and biomedical aids and vehicles.  
Size of the droplets is governed by the surfactant phase structure (bicontinuous microemulsion or lamellar) at the 
inversion point induced by either temperature or composition
2
. They are composed of an oil phase, aqueous phase, 
surfactant and co surfactant at appropriate ratios. The particles can exist as water in-oil and oil-in-water forms, 
where the core of the particle is either water or oil, respectively
3
. 
Nanoemulsions are based on low interfacial tension, achieved by adding a co-surfactant, which leads to spontaneous 
formation of a thermodynamically stable nanoemulsion. Nanoemulsions have high kinetic stability, low viscosity, 
and transparency/ translucency, are very attractive for a range of industrial applications, including the 
pharmaceutical field where they have been explored as drug delivery systems. The Nanoemulsions are also termed 
as mini emulsions, ultrafine emulsions and submicronemulsions
4
.  
Carvedilol is a non-selective beta blocker used in the treatment of mild to moderate congestive heart failure and mild 
to moderate essential hypertension
5
. It is a poor water- soluble and highly permeable drug. Its oral bioavailability is 
low (23%) because of significant first-pass hepatic metabolism by cytochrome P450
6, 7
. However, some sources 
suggest that this low bioavailability is the result of poor aqueous solubility. It is practically insoluble in water (0.583 
mg/L)  and have pH-dependent solubility. Carvedilol also has a short plasma half-life of 7-10 hrs. Many parameters 
like low oral dose (6.25–25.0 mg), suitable log P (octanol/ water) of 4.19, low oral bioavailability and the condition 
of being a BCS class II drug make it suitable candidate to use it for the development of Nanoemulsions
8
. 
The aim of this study was to assess the feasibility of preparing Carvedilol nanoemulsion by aqueous phase titration 
method, and the physicochemical properties of obtained Carvedilol loaded nanoemulsions, such as particle size, 
viscosity, polydispersity, zeta potential, in vitro drug release behavior.  
MATERIALS AND METHODS 
Carvedilol was obtained from Olex pharmaceuticals, Nigeria as gift sample. Castor oil, clove oil, silicon oilwere 
purchased from Omolad Oli Nig Ltd, Nigeria. PEG-600,  PEG-400, PEG 200,  80, tween 20, span 60 were 
purchased from Agmont Industries Nig Limited, Nigeria. 
 
SCREENING OF OILS, SURFACTANTS AND CO-SURFACTANTS FOR NANOEMULSION 
Solubility studies
9 
The solubility of Carvedilol in various oils (Capryol 90, Isopropyl myristate, Oleic acid, Olive oil, Sunflower oil and 
Linseed oil), surfactants (Tween 20 and Tween 80) and cosurfactants (Transcutol P, Propylene glycol, PEG 400 and 
Glycerol) was determined by adding an excess amount of drug in oils, surfactants and co surfactants separately in 
stopper vials, and mixed. The mixture vials were then kept at 25 ± 1.0°C in an Orbital shaker for 72 hrs to reach 
equilibrium. The samples were removed after achieving equilibrium and centrifuged at 3000 rpm for 15 min. The 
supernatant was taken and filtered through a 0.45-μm membrane filter. The filtrate was solubilized in suitable 
solvent, diluted with the pH 7.4 buffer and the concentration of Carvedilol wasdetermined using UV-Visible 
spectrophotometer (Finlab Ltd, Nigeria) at 241 nm. 
 
 
 
 
 
 
 
 
Table 1: Solubility of carvedilol in different oils, surfactants and cosurfactants 
S.N. Oils Solubility (mg/ ml) Surfactants Solubility (mg/ ml) 
1.  Silicon oil  0.48 ± 0.18 Span-80  46.58 ± 0.38 
2.  Eucalyptus oil  4.62 ± 0.39 Tween-80  28.94 ± 0.49 
3.  Clove oil  159.63 ± 1.4 Tween-20  84.94 ± 0.97 
4.  Castor oil  16.38 ± 0.91 Cosurfactants Solubility (mg/ ml) 
5.  Olive oil  9.35 ± 0.38 PEG-600  141 ± 1.7 
6.  Capmul MCMC8  29.53 ± 0.84 PEG-400  230.57 ± 0.64 
7.  Isopropyl myristate (IPM) 11.48 ± 0.66 PEG-200  189.08 ± 0.38 
8.  Triacetin  11.89 ± 1.59 Propylene glycol  9.56 ± 0.89 
Mean ± SD, n=3 
 
Selection of Surfactant
10
  
Surfactant selection was done on the basis of percentage of transparency (% transparency) 
and ease of emulsification. Briefly, 0.3 ml of each surfactantwas added to the selected 0.3 
ml of oil phase. The mixture was gently heated at 50ºC for homogenization of the components. 
Each 0.05 ml mixture was then diluted with water in a stoppered conical flask. Ease of 
emulsification was judged by the number of flask inversion required to yield a homogenous 
emulsion. Emulsion is allowed to stand for 2 hours and their % transparency was evaluated 
by UV spectrophotometer using distilled water as a blank at 241 nm. 
Selection of Co-surfactant
11
  
Screening of co-surfactant was conducted on the basis of % transparencyand ease of 
emulsification. 0.1 ml of each cosurfactant mixed with 0.2 ml of selected surfactant and the 
0.3 ml of selected oil phase was added and evaluated in a similar fashion as described in the  
above section of surfactant. 
Construction of phase diagrams
12
  
Pseudo ternary phase diagrams were constructed for 1:1, 1:2 and 1:3 surfactant to cosurfactant ratios (Smix). So that 
nanoemulsion regions could be identified. In construction of phase diagrams clove oil was used as oil, tween 20 was 
used as surfactants and PEG 400 was used as cosurfactant. 
  
 
   
                   (a). Smix 1:1                                                (b). Smix 1:2                                    (c).  Smix 1:3 
Figure 1: Pseudo Ternary phase diagram of clove oil, tween 20, PEG 400 and water   
Preparation of nanoemulsions
12 
Nanoemulsions were prepared by aqueous phase titration method. The composition of the 
nanoemulsions was chosen according to the pseudo ternary phase diagram. Thedrug was dissolved in the oil, 
surfactant and co-surfactant mixture was added in the chosen concentration, and water was added drop wise with 
continuous stirring until clear nanoemulsion was formed. Resulting carvedilol containing nanoemulsion was 
subjected to homogenization for 10 minutes using ultra turrex (Silverson, U.K) at 8000 rpm to get uniform and 
stable nanoemulsion
13
. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Different Smix ratio (clove oil, tween 20, PEG 400) 
Oil : S/ 
COS 
Formulation 
code 
Oil 
(mg) 
Surfactanct 
(mg) 
Cosurfactant 
(mg) 
Water (% w/w) 
Smix  Ratio 1:1 
0.5:9.5 NEA1 0.050 0.420 0.525 54.5 
2:8 NEA2 0.198 0.370 0.396 56.7 
4:6 NEA3 0.396 0.295 0.295 60.00 
6:4 NEA4 0.594 0.385 0.196 59.25 
Smix  Ratio 1:2 
0.5:9.5 NEB1 0.050 0.314 0.626 52.84 
2:8 NEB2 0.198 0.264 0.528 57.52 
4:6 NEB3 0.396 0.198 0.396 51.35 
6:4 NEB4 0.594 0.132 0.264 52.66 
Smix  Ratio 1:3 
0.5:9.5 NEC1 0.050 0.626 0.314 54.32 
2:8 NEC2 0.198 0.528 0.264 57.22 
4:6 NEC3 0.396 0.396 0.198 58.12 
6:4 NEC4 0.594 0.145 0.132 60 
 
CHARACTERIZATION OF NANOEMULSION
 
Nanoemulsions are thermodynamically stable systems and are formed at a particular concentration of oil, surfactant 
and water, with no phase separation, creaming or cracking. It is the thermostabilitywhich differentiates 
nanoemulsions from emulsions that have kinetic stability and will eventually phase separate. Thus, the selected 
formulations were subjected to different thermodynamic stability by using heating cooling cycle, centrifugation and 
freeze thaw cycle  stress tests.  
a). Centrifugation test: Nanoemulsions were centrifuged for 20 min at 3000 rpm and checked for phase separation, 
creaming or cracking14. 
b). Freezing–thawing test: The formulations were subjected to two different temperatures which are (21oC) and (-
21
 o
C) using refrigerator and the time for each temperature not less than 24 hours. This test used to indicate 
accelerated stability of formulations
15
. 
c). Heating-cooling test: This test was done by keeping the formulations at 40 oC and at 0 oC by refrigerator for 48 
hours. This test used to indicate the racking effect on the formulations stability15. 
Optimized formulations were taken for viscosity, refractive index, transmittance and in vitro release studies. 
Preparation of Carvedilol loaded nanoemulsion:  
Carvedilol nanoemulsions were produced by dissolving the quantity of drug in specialized amount of oil. Then the 
determined quantity of Smix added for oil loaded drug, after that the whole mixture was blended together by vortex 
mixer (Mon Scientific, Nigeria), at the speed of 100 rpm. Then theaqueous phase (deionized water) titrated drop by 
drop to obtain transparent, clear (o/w) nanoemulsion. 
 
Table 3: Thermodynamic stability tests for nanoemulsion formulations of pseudo ternary phase diagram 
Code Thermodynamic stability test Results 
 Centrifuge  Freeze 
thawing 
Heating- 
cooling 
 
NEA1    Pass 
NEA2    Fail 
NEA3    Pass 
NEA4    Pass 
NEB1    Fail 
NEB2    Pass 
NEB3    Pass 
NEB4    Fail 
NEC1    Pass 
NEC2    Pass 
NEC3    Fail 
NEC4    Pass 
 
Particle size and zeta potential (ZP) measurement
16 
An amount of 0.1 ml of each tested formulation was dispersed in 50 ml of water in volumetric flask and then mixed 
by inverting the flask. Globule size and zeta potential of the nanoemulsion was determined by particle size analyzer 
 
(QL-1076, Nigeria) that analyzes the fluctuations in  light scattering due to Brownianmotion of the particles. Light 
scattering was monitored at 25 °C at a 90° angle. 
Poly dispersity index (PDI) assay
17
  
This assay is used to measures the uniformity of globules size in nanoemulsion. It can be obtained by ABT-9000 
nanolaser particle size analyzer. The higher the poly dispersity value  refers to the lower uniformity ofglobules size 
of nanoemulsion. 
Determination of pH  
The pH value plays important role in determination of the stability of the nanoemulsion. Change in pH means 
occurrence of chemical reactions that can impair the quality of the final product. The digital pH meterwas used to 
determine the pH of the formulations.  
Refractive Index 
Refractive Index was determined using Abbe's refractometer at 25°C. 
Viscosity
18 
Viscosity of the samples was measured as such without dilution using Brookfield viscometer at 25°C. A sample 
volume of 10 ml was used. The nanoemulsion formulations were subjected to different rpm (5, 10, 20, 30, 50, 60 
and 100) and the rheological behavior of the disperse system was examined by constructing rheograms of shear 
stress vs. shear rate. 
Drug content
19
  
Drug content of RF in nanoemulsion was measured by using UV visible spectrophotometer at 241 nm. About 0.1 
mL of the formulation was suitably diluted with 5 mL in pH 7.4 phosphate  buffer andanalyzed for drug content. 
Table 4 : Droplet size, polydispersity, viscosity, and RI of nanoemulsion 
Code Droplet size 
(nm) 
Polydispersity 
index (PDI) 
Viscosity 
(mPa s) 
RI % 
Transmittance 
ZP 
(Mv) 
pH % Drug 
content 
NEA1 80.81  ± 0.85 0.163 60.42  ± 
0.88 
1.312 ± 
0.006 
95.42 ± 0.08 -18.34 
±1.46 
5.43  ± 0.08 98.46 ± 0.04 
NEA3 78.47  ± 2.4 0.167 120.45  ± 
2.7 
1.302 ± 
0.009 
98.24 ± 0.13 -21.54 
±3.41 
6.23  ± 0.07 97.64 ± 0.12 
NEA4 77.39  ± 0.77 0.093 128.58  ± 
1.5 
1.334 ± 
0.008 
97.57 ± 0.09 -22.66 
±2.58 
5.51  ± 0.04 99.04 ± 0.08 
NEB2 74.45  ± 3.6 0.173 134.63  ± 
3.8 
1.327 ± 
0.007 
96.89 ± 0.04 -25.37 
±1.49 
6.13  ± 0.12 98.27 ± 0.05 
NEB3 73.48  ± 4.8 0.094 129.34  ± 
4.7 
1.315 ± 
0.004 
97.33 ± 0.21 -26.47 
±2.37 
5.72  ± 0.21 99.23 ± 0.01 
NEC1 70.85  ± 0.68 0.166 129.42  ± 
3.8 
1.408 ± 
0.009 
94.32 ± 0.57 -24.11 
±2.64 
5.33  ± 0.09 96.48 ± 0.04 
NEC2 69.07  ± 1.6 0.088 98.53  ± 
2.6 
1.351 ± 
0.003 
96.22 ± 0.82 -25.73 
±1.39 
6.21  ± 0.07 98.72 ± 0.06 
NEC4 68.42  ± 2.8 0.164 60.53  ± 
1.8 
1.293 ± 
0.006 
98.68 ± 0.18 -22.39 
±0.82 
5.66 ± 0.31 97.65 ± 0.07 
 
 
In vitro drug release studies
20, 21
  
The in vitro drug release of Carvedilol from the nanoemulsion formulation was determined by  
dialysis bag method. The dissolution study was performed for 12 hrs. In this method 0.1N HCl and pH 7.4 
phosphate buffer maintained at 37°C and stirred with amagnetic stirrer ( STUART, Finlab, Nigeria) was selected as 
in vitro release medium. About 1 mL of formulation was placed in the dialysis bag which was immersed in 50 mL of 
0.1 N HCl.  Samples (2 mL) were withdrawn at predetermined time intervals and replenished with equal volume of 
fresh medium. The samples were analyzed by the UV-Visible spectrophotometer at 241 nm todetermine the 
Carvedilol content. 
 
 
Figure 2: In vitro dissolution profiles of Carvedilol nanoemulsion formulations of batch NEA1-NEB2 
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Figure 3: In vitro dissolution profiles of Carvedilol nanoemulsion formulations of batch NEB3-NEC4 
Kinetics models and drug release mechanism
22
:  
Determination of release kinetic of drug wasdone by using various kinetics models. The results of dissolution must 
be fitted for these kinetics models which are (zero order kinetic, first order kinetic, Higuchi model). 
Table 5: Values of regression coefficient (R
2
) and values of diffusion exponent (n) 
Code Zero order 
kinetic 
First order 
kinetic 
Higuchi model Diffusion 
exponent 
 R
2 
R
2 R2 N 
NEA1 0.972 0.915 0.923 0.26 
NEA3 0.986 0.938 0.953 0.28 
NEA4 0.967 0.945 0.964 0.41 
NEB2 0.987 0.963 0.954 0.29 
NEB3 0.978 0.972 0.895 0.36 
NEC1 0.983 0.942 0.948 0.28 
NEC2 0.982 0.961 0.925 0.14 
NEC4 0.985 0.972 0.935 0.34 
(P<0.05) 
 
Statistical analysis 
All the data generated were expressed as mean ± standard deviation. Threegroup comparisons, one-way analysis of 
variance with duplication was applied. Statistical significance was determinedusing Student’s t-test, with P<0.05 
considered to be statistically significant. 
RESULTS AND DISCUSSION  
Drug solubility in oils plays and important role, as the ability of the nanoemulsion to maintain the drug in 
solubilized form depends on the solubility of the drug in the oil phase. In case of inadequate solubilization, there 
may be chances of precipitation, particularly in case of oral or parenteral nanoemulsion. After screening the oils for 
carvedilol solubility, it was found that carvedilol exhibited maximum solubility in clove oil (table 1).  Hence clove 
oil was chosen as the oil phase.  Similarly based on solubilityparameter tween 20 was used as surfactants and PEG 
400 was used as cosurfactant. 
The components of pseudo-ternary phase plot (figure 1) are oil, water and Smix (surfactant /co surfactant) which 
considered as variable component due to that it presents in different ratio such as 1:1, 1:2, 1:3 as shown in figure 1. 
The shaded area represents the area of nanoemulsion and the larger shaded area indicates a good nanoemulsifying 
activity. Based on the results of thermodynamic stability tests as shown in table 3, eight formulations were selected 
for preparation of carvedilol loaded nanoemulsions and these nanoemulsions were subjected for characterization. 
Different results are shown in table 4, i.e. droplet size, PDI, pH and % transmittance etc.  For carvedilol loaded 
nanoemulsions explains that the droplets size was decrease with increase in the Smix ratio.  
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 2 4 6 8 10 12 
C
u
m
u
la
ti
v
e 
%
 D
ru
g
 R
el
ea
se
d
 
Time (Hrs) 
NEB3 
NEC1 
NEC2 
NEC4 
 
The results of PDI as shown in table 4 indicate the uniformity of droplets distribution within the formulations. All 
formulations have PDI value less than (1.0). The lower value of PDI was (0.088) for NEC2, this explains that NEC2 
has higher uniformity of droplets distribution within formulation. The results of viscosity of carvedilol 
nanoemulsions were found to be in range (60.42 –134.63 m Pa.sec.). Viscosity has an important aspect to ensure the 
smoothen formulations, packing23. The refractive index of the formulated nanoemulsion was similar to the refractive 
index of the water (1.333). The results of % transmittance explain that the formulated nanoemulsions were clear and 
transparent, and the transparency of nanoemulsions indicates that the droplets size was in nano-scale. The higher 
value of % transmittance in carvedilol loaded nanoemulsions was (98.68 %)  for NEC4.The results of pH 
measurement for formulations explain that the pH values of drug free nanoemulsions was slightly acidic. The higher 
pH value in the formulations of carvedilolnanoemulsions was (6.23) for NEA3 and this pH value is suitable for oral 
administration.  
Zeta potential of different formulations was calculated to explain the electro kinetic potential in colloidal 
dispersions. The results of zeta potential of carvedilol nanoemulsions were in range -18.34 mV to -26.47 mV). 
According to rule of thumb, the values of zeta potential which are: range -5 mV to +5 mV indicate fast aggregation, 
about -20 mV or +20 mV provide short term stability, above +30 mV or below -30 mV indicate a good stability and 
above +60 mV or below -60 mV offers excellent stability24.  
The results of drug content in nine formulations of carvedilol loaded nanoemulsions were in range (92.1- 98.9%). 
The higher percent of drug content (99.04 %) was found in NEA4 that has S mix (1:1), and the lowest percent of 
drug content (96.48 %) was found in NEC1 that has S mix (1:3). A 12 hrs in-vitro release release study was 
performed on selected nanoemulsion formulations of carvedilol (Figure 2 and 3). The highest in-vitro release is 
shown by formulation of batch NEC4 (84.57 %), while the lowest release is shown by NEA4 (42.786 %). 
Analysis of variance (ANOVA), study was performed by means of ezANOVA software. It reveals that there was a 
significant difference (P<0.05) between the release of carvedilol in all formulations. 
The release of drug from carvedilol nanoemulsions in dissolution media explains the influence of surfactant 
concentration on the release of carvedilol for each ratio of Smix. In each Smix ratio, as the concentration of tween 20 
increase, the release of carvedilol decrease. 
This may be due to increasing the concentration of tween 20 results in increasing the diffusion of  
carvedilol molecules from dialysis bag for the dissolution medium15. 
The data of dissolution were fitted for various kinetic models (table 5. It was found that the higher regression 
coefficient (R
2
) values in the zero order kinetic. So, the kinetic of drug release in all Nanoemulsions was zero- order 
kinetic and the values of diffusion exponent (n) for all nanoemulsions of carvedilol was significantly lower than 0.41 
(P<0.05), this explains that the mechanism of release of nimodipine from nanoemulsion formulations  was Fikian 
release (diffusion). 
CONCLUSION 
Nanoemulsions are considered as an advance technique for improving thebioavailability of poorly water - soluble 
drugs by enhancing the solubility and minimizing the first pass metabolism. A correct combination of oil, surfactant, 
cosurfactant, and water is a major consideration factor in nanoemulsion preparation. Clove oil, tween 20, PEG 400 
were selected for preparation of nanoemulsion by aqueous phase titration method. On the basis of different in-vitro 
release study, carvedilol nanoemulsion formulation of batch NEC4 (Smix  Ratio 1:3) was found to be optimum 
formulation. The optimized formulation showed low particle size, low viscosity and high percentage transmittance.  
The present study was clearly indicated that the usefulness ofnanoemulsion in the improvement of the solubility, 
dissolution rate and there by oral bioavailability of carvedilol. 
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